STOCK TITAN
  1. Home
  2. Sec-filings
  3. KROS
  4. [Form 4] Keros Therapeutics, Inc. Insider Trading Activity

Keros director receives RSU and option grants

Keros Therapeutics director Julius Knowles reported new equity awards and updated his holdings.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Keros Therapeutics director Julius Knowles reported new equity awards and updated his holdings. He received 7,142 restricted stock units that vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as he continues serving the company.

He also received a stock option covering 7,433 shares of common stock at an exercise price of $10.50 per share. This option vests in equal quarterly installments over the 12 months following June 3, 2026 and will in any case be fully vested by the 2027 annual meeting, subject to continued service. After these grants, he directly holds 13,583 common shares and also has indirect interests in 102,233 and 150,047 shares held by Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P., where he may share voting and investment power.

Positive

  • None.

Negative

  • None.
Insider Knowles Julius
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 7,433 $0.00 $0.00
Grant/Award Common Stock 7,142 $0.00 $0.00
holding Common Stock -- -- --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 7,433 contracts (Direct); Common Stock — 13,583 shares (Direct); Common Stock — 252,280 shares (Indirect, See footnote)
Footnotes (4)
  1. F1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
  2. F2. The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
  3. F3. The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
  4. F4. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
RSU grant 7,142 shares Restricted stock units awarded on June 3, 2026
Stock option grant 7,433 options Right to buy common stock granted on June 3, 2026
Option exercise price $10.50 per share Conversion or exercise price for 7,433-share option
Direct common shares after grant 13,583 shares Total direct holdings of common stock after RSU grant
Indirect holdings via Partners Innovation Fund, LLC 102,233 shares Common stock held by PIF I where voting and investment power may be shared
Indirect holdings via Partners Innovation Fund II, L.P. 150,047 shares Common stock held by PIF II where voting and investment power may be shared
Option expiration date June 2, 2036 Expiration of 7,433-share stock option if unexercised
restricted stock unit ("RSU") financial
"Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027..."
Partners Innovation Fund, LLC ("PIF I") financial
"The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner..."
Partners Innovation Fund II, L.P. ("PIF II") financial
"The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner..."
Stock Option (right to buy) financial
"Stock Option (right to buy)... underlying security title: "Common Stock" and underlying security shares: "7433.0000""
annual meeting of stockholders financial
"The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders..."
voting and investment power financial
"may be deemed to share voting and investment power with respect to the shares held by PIF I."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Julius Knowles receive from Keros Therapeutics (KROS)?
Julius Knowles received a grant of 7,142 restricted stock units and a stock option for 7,433 shares at an exercise price of $10.50 per share, both awarded on June 3, 2026 as part of his director compensation.

When do Julius Knowles’ Keros Therapeutics RSUs vest?
The 7,142 restricted stock units fully vest on the earlier of June 3, 2027 or the Keros Therapeutics 2027 annual meeting of stockholders, provided Julius Knowles continues to provide service to the company through that date.

How do Julius Knowles’ new Keros stock options vest and when do they expire?
The option for 7,433 shares vests in equal quarterly installments over 12 months following June 3, 2026 and will be fully vested by the 2027 annual meeting. It expires on June 2, 2036 if not exercised earlier.

How many Keros Therapeutics shares does Julius Knowles hold after these transactions?
Following the reported awards, Julius Knowles directly holds 13,583 shares of Keros Therapeutics common stock. He also has indirect interests in 102,233 and 150,047 shares held by Partners Innovation Fund entities with which he may share voting and investment power.

What are Partners Innovation Fund entities’ roles in Julius Knowles’ Keros holdings?
Shares are held by Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P. Their general partners are affiliated entities where Julius Knowles is a partner, so he may be deemed to share voting and investment power over those Keros Therapeutics shares.

Are Julius Knowles’ recent Keros equity transactions open-market buys or sales?
No open-market buys or sales are reported. The Form 4 details compensation-related grants: restricted stock units and a stock option award. These increase his equity exposure without reflecting discretionary market purchases or sales of Keros Therapeutics shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Knowles Julius
(Last)(First)(Middle)
C/O KEROS THERAPEUTICS, INC.
1050 WALTHAM STREET, SUITE 302
(Street)
LEXINGTON MASSACHUSETTS 02421
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/03/2026A7,142(1)A$013,583D
Common Stock150,047ISee footnote(2)
Common Stock102,233ISee footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$10.506/03/2026A7,433 (4)06/02/2036Common Stock7,433$07,433D
Explanation of Responses:
1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
2. The securities are held by Partners Innovation Fund, LLC ("PIF I"). Partners Innovation Fund, LLC ("Partners GP I") is the ultimate general partner of PIF I. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP I and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF I.
3. The securities are held by Partners Innovation Fund II, L.P. ("PIF II"). Partners Innovation Fund II, LLC ("Partners GP II") is the ultimate general partner of PIF II. The Reporting Person, a member of the board of directors of the Issuer, is a partner of Partners GP II and as a result, may be deemed to share voting and investment power with respect to the shares held by PIF II.
4. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
/s/ Keith Regnante, Attorney-in-Fact06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Keep reading

More on KROS

Trending in the feed

Open the live feed